The effect of smoking on COVID-19 severity: A systematic review and meta-analysis.

Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. · 2021

Read The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. by Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7436545.txt.

Introduction

Reddy and co-authors pool studies on smoking and COVID-19 severity. Early meta-analyses on this question were small and weak in method. The team searched four databases for studies of hospitalized patients.

They analyzed 47 studies with data on smoking and disease outcomes. Current smokers had higher risk of severe COVID-19, with a risk ratio of 1.80. People with any smoking history faced more severe disease, more deaths in hospital, and more disease progress. They also needed mechanical ventilation more often. The authors conclude that current and former smokers are a high-risk group. Prevention and support for these patients matter most while no targeted therapies exist.

Catalog record

CREATORReddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7436545

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The effect of smoking on COVID‐19 severity: A systematic review and meta‐analysis By Rohin K. Reddy, Walton N. Charles, Alexandros Sklavounos, Atul Dutt, Paul T. Seed, Ankur Khajuria Published in: Journal of Medical Virology DOI: 10.1002/jmv.26389 ABSTRACT Abstract Various comorbidities represent risk factors for severe coronavirus disease 2019 (COVID‐19). The impact of smoking on COVID‐19 severity has been previously reported in several meta‐analyses limited by small sample sizes and poor methodology. We aimed to rigorously and definitively quantify the effects of smoking on COVID‐19 severity. MEDLINE, Embase, CENTRAL, and Web of Science were searched between 1 December 2019 and 2 June 2020. Studies reporting smoking status of hospitalized patients with different severities of disease and/or at least one clinical endpoint of interest (disease progression, intensive care unit admission, need for mechanical ventilation, and mortality) were included. Data were pooled using a random‐effects model. This study was registered on PROSPERO: CRD42020180920. We analyzed 47 eligible studies reporting on 32 849 hospitalized COVID‐19 patients, with 8417 (25.6%) reporting a smoking history, comprising 1501 current smokers, 5676 former smokers, and 1240 unspecified smokers. Current smokers had an increased risk of severe COVID‐19 (risk ratios [RR]: 1.80; 95% confidence interval [CI]: 1.14‐2.85; P = .012), and severe or critical COVID‐19 (RR: 1.98; CI: 1.16‐3.38; P = .012). Patients with a smoking history had a significantly increased risk of severe COVID‐19 (RR: 1.31; CI: 1.12‐1.54; P = .001), severe or critical COVID‐19 (RR: 1.35; CI: 1.19‐1.53; P < .0001), in‐hospital mortality (RR: 1.26; CI: 1.20‐1.32; P < .0001), disease progression (RR: 2.18; CI: 1.06‐4.49; P = .035), and need for mechanical ventilation (RR: 1.20; CI: 1.01‐1.42; P = .043). Patients with any smoking history are vulnerable to severe COVID‐19 and worse in‐hospital outcomes. In the absence of current targeted therapies, preventative, and supportive strategies to reduce morbidity and mortality in current and former smokers are crucial. INTRODUCTION As of 28 July 2020, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has infected 16 341 920 patients, with 650 805 deaths across 188 countries. 1 , 2 Risk factors for poor outcome in patients with coronavirus disease 2019 (COVID‐19) include older age, male sex, hypertension, diabetes, cardiovascular disease, and respiratory disease. 3 , 4 , 5 Remarkably, current peer‐reviewed data surrounding the effect of smoking tobacco on the clinical severity of COVID‐19 has thus far been controversial, and there is an urgent need for definitive answers. 6 An early systematic review without meta‐analysis concluded that smoking is most likely associated with negative progression and outcomes in COVID‐19, 7 however, a preliminary meta‐analysis showed that active smoking is not significantly associated with increased risk of severe disease. 8 Four subsequent meta‐analyses have shown an increased risk of severe COVID‐19 associated with smoking. 9 , 10 , 11 , 12 A summary of the six previously published systematic reviews 7 , 8 , 9 , 10 , 11 , 12 alongside assessment of their methodological quality using A Measurement Tool to Assess systematic Reviews 2 13 (AMSTAR 2) is provided in the Appendix (Appendix pp2‐3). The articles ranged from critically poor to moderate quality, indicating that significant methodological flaws in critical domains exist with all six currently published reviews assessing the impact of smoking on COVID‐19 severity. It is therefore likely that the true effect of smoking on COVID‐19 severity reported in these analyses is clouded by considerable bias. Furthermore, as a result of several nonpeer reviewed preprint articles falsely equating the prevalence of smoking in COVID‐19 study populations with population estimates for smoking prevalence, there has been widespread attention paid to recent mass media reports that smoking may exert a protective effect against COVID‐19 infection. 14 This led to the World Health Organization releasing a statement on 11 May urging caution with regards to these claims, and emphasizing the lack of evidence confirming a link between smoking or nicotine in the prevention or treatment of COVID‐19. 15 Consequently, there remains a distinct lack of clarity and high‐quality evidence regarding the relationship between smoking and the severity of COVID‐19. Therefore, to address this important clinical question, this systematic review and meta‐analysis aimed to evaluate the effect of smoking status, including current smoking and a history of smoking, on the clinical severity of COVID‐19. METHODS Search strategy and selection criteria This systematic review and meta‐analysis adhered to PRISMA guidelines 16 and was AMSTAR 2 compliant (Appendix pp8‐12). 13 Two authors independently searched MEDLINE, Embase, CENTRAL, and Web of Science for studies published between 1 December 2019 and 2 June 2020. The search strategy is provided in the Appendix (p13). No language restrictions were applied. COVID‐19 resource centers of The Lancet, The Lancet Respiratory Medicine, The New England Journal of Medicine, and The BMJ were also hand searched up to 5 July 2020. Reference lists of included studies and previous systematic reviews were additionally screened for their relevance. To capture all available relevant evidence, randomized, and observational studies reporting the smoking status of hospitalized patients presenting with different severities of disease and/or at least one clinical endpoint of interest were deemed eligible for inclusion. Smoking history included current and former tobacco smokers or e‐cigarette users. Disease severity, including severe or critical cases, was defined a priori and based on the COVID‐19 diagnostic criteria issued by the Chinese National Health Commission (Appendix p13). 17 Other acceptable criteria included the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) criteria for severe community‐acquired pneumonia. 18 Clinical endpoints of disease progression, intensive care unit (ICU) admission, mechanical ventilation requirement, and/or mortality were used as surrogate markers for in‐hospital severity. We excluded studies on other coronaviruses or if there was insufficient information to distinguish disease severity based on smoking status. Case series involving less than 20 patients, review articles, editorials, conference abstracts, and nonclinical studies were also excluded. Preprints were not assessed for eligibility due to their preliminary nature. Two authors (WNC, AS) independently screened the titles and abstracts of retrieved studies, with full‐texts of all potentially eligible papers subsequently assessed for inclusion. Any discrepancy was resolved by consensus discussion with the senior author (AK). Data analysis Data from studies that fulfilled our inclusion criteria were extracted independently by three authors (WNC, AS, and RKR). Main data‐points included: study details (author, journal, date, country, study design, study period, and funding), total numbers of patients, and their clinical outcomes by smoking status. Two authors (AS and AD) independently assessed the quality of included studies using the Newcastle‐Ottawa Scale modified for case series, cohort studies, and cross‐sectional studies. 19 Scores were then classified by the Agency for Healthcare Research and Quality standards as good, fair, or poor. Any discrepancies in quality assessment were resolved by a third author (WNC). As per our prespecified analysis plan, random‐effects meta‐analyses of pooled raw data were employed using the DerSimonian and Laird method for each outcome with sufficient data to account for anticipated differences across countries and study design over time. Current smokers were compared to former and never‐smokers, and patients with a smoking history were compared to never‐smokers. Where available, adjusted effect estimates were combined and in the absence of adjustment for confounders, raw effect estimates were combined. The results are presented in forest plots as risk ratios (RR) and corresponding

Read the complete text